We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00750555
Recruitment Status : Terminated (Dr. Amy Law left Geisinger Health System. 4 patients enrolled)
First Posted : September 10, 2008
Last Update Posted : October 11, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: Erlotinib Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Study Start Date : September 2008
Primary Completion Date : December 2009
Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
1 Drug: Erlotinib
150 mg per day orally until disease progression occurs, up to a maximum of 12 months
Other Name: Tarceva

Outcome Measures

Primary Outcome Measures :
  1. One year disease free [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 2 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage III, IV SCCHN
  • Completed curative treatment

Exclusion Criteria:

  • Prior chemotherapy or radiotherapy
  • Recurrent disease
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00750555

United States, Pennsylvania
Geisinger Health System
Danville, Pennsylvania, United States, 17822
Sponsors and Collaborators
Geisinger Clinic
Genentech, Inc.
Principal Investigator: Amy Law, MD Geisinger Clinic
More Information

Additional Information:
Responsible Party: Geisinger Clinic
ClinicalTrials.gov Identifier: NCT00750555     History of Changes
Other Study ID Numbers: 2008-0153
First Posted: September 10, 2008    Key Record Dates
Last Update Posted: October 11, 2012
Last Verified: October 2012

Keywords provided by Geisinger Clinic:
squamous cell cancer of head and neck

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action